Study guide

4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders

Key Takeaways Explain This Topic AI

Polycystic ovary syndrome (PCOS) is a complex neuroendocrine and metabolic disorder characterized by ovarian thecal cell androgen hypersecretion, accelerated LH pulsatility, and compensatory hyperinsulinemia.

Under the 2003 Rotterdam consensus criteria, diagnosis requires at least two of three cardinal features: ovulatory dysfunction (oligo- or anovulation), clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on transvaginal ultrasound (>=20 follicles per ovary measuring 2–9 mm or ovarian volume >=10 mL), after excluding mimickers.

Differential diagnosis requires targeted laboratory exclusions: 17-hydroxyprogesterone to rule out non-classic congenital adrenal hyperplasia (NCCAH), serum prolactin for hyperprolactinemia, TSH for thyroid disease, and rapid virilization workup (total testosterone >200 ng/dL or DHEAS >700 mcg/dL) for androgen-secreting neoplasms.

Metabolic sequelae mandate universal screening with a 2-hour 75g oral glucose tolerance test (OGTT) due to high rates of impaired glucose tolerance and type 2 diabetes, along with lipid profiling, non-alcoholic fatty liver disease (NAFLD) surveillance, and endometrial protection against unopposed estrogen.

Multimodal management prioritizes lifestyle modification (5%–10% weight loss restores ovulation in up to 50% of overweight patients); combined oral contraceptives (COCs) serve as first-line therapy for cycle control and hirsutism; spironolactone provides anti-androgen therapy with strict contraception; and letrozole is the first-line ovulation induction agent for fertility.

Last updated: October 2026

Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine and reproductive disorder among women of reproductive age, affecting approximately 8% to 13% globally. It is a heterogeneous metabolic and neuroendocrine disorder characterized by the interplay of thecal cell androgen hypersecretion, accelerated hypothalamic-pituitary gonadotropin pulsatility, and peripheral insulin resistance with compensatory hyperinsulinemia.

Important

PCOS is fundamentally a diagnosis of exclusion. Clinicians must rule out non-classic congenital adrenal hyperplasia (NCCAH), hyperprolactinemia, thyroid disorders, Cushing syndrome, and androgen-secreting ovarian or adrenal neoplasms before establishing a diagnosis.

Pathophysiology & Neuroendocrine Dysregulation

The pathophysiology of PCOS spans ovarian, neuroendocrine, and systemic metabolic pathways:

Thecal Cell Hyperactivity: Ovarian theca interna cells constitutively overexpress steroidogenic enzymes, particularly CYP17A1 (17-alpha-hydroxylase and 17,20-lyase), driving excessive conversion of progestins to androstenedione and testosterone.

Accelerated GnRH Pulsatility: Rapid hypothalamic GnRH pulses favor pituitary gonadotrope synthesis of luteinizing hormone (LH) over follicle-stimulating hormone (FSH). This elevates the circulating LH:FSH ratio (characteristically 2:1 or 3:1).

Follicular Arrest: Relative FSH deficiency prevents adequate induction of CYP19A1 (aromatase) in granulosa cells. Without sufficient aromatization of androgens to estrogens, follicular development arrests in the preantral and early antral stage (2 to 9 mm), producing chronic anovulation and polycystic ovarian morphology.

Hyperinsulinemia & Reduced SHBG: Peripheral insulin resistance triggers compensatory hyperinsulinemia. Insulin acts as a co-gonadotropin on thecal insulin and IGF-1 receptors to amplify LH-stimulated androgen production. Concurrently, insulin downregulates hepatic synthesis of sex hormone-binding globulin (SHBG) , markedly increasing circulating free, biologically active testosterone.

Unopposed Estrogen: Peripheral adipose tissue converts androgens into estrone via aromatase. Persistent, non-cyclic estrogen without cyclical progesterone secretory differentiation promotes continuous mitogenic endometrial stimulation, raising the risk of endometrial hyperplasia and type 1 adenocarcinoma.

Diagnostic Criteria: The Rotterdam Consensus

According to the 2003 Rotterdam Consensus , diagnosis requires at least 2 of the following 3 features , after excluding alternative etiologies:

Ovulatory Dysfunction: Oligo- or anovulation (cycles >35 days, <8 cycles per year, or amenorrhea >=90 days).

Clinical and/or Biochemical Hyperandrogenism:

Clinical: Hirsutism quantified by a modified Ferriman-Gallwey (mFG) score of ≥4–6 (2023 International PCOS Guideline; cutoffs vary by ethnicity), severe inflammatory/cystic acne, or androgenetic alopecia.

Biochemical: Elevated total/free testosterone or Free Androgen Index (FAI = [total testosterone / SHBG] x 100 >5).

Polycystic Ovarian Morphology (PCOM): Transvaginal ultrasound demonstrating >=20 follicles per ovary measuring 2 to 9 mm throughout the entire ovary, AND/OR an increased ovarian volume >=10 mL in either ovary (excluding dominant follicles >10 mm or corpus luteum). The 2023 International PCOS Guideline also allows an elevated serum anti-Müllerian hormone (AMH) to stand in for ultrasound PCOM in adults.

Note

In adolescents within 8 years of menarche, pelvic ultrasound is not recommended due to physiologic multicystic ovaries. Diagnosis in adolescents requires both ovulatory dysfunction and clinical or biochemical hyperandrogenism.

Rotterdam PCOS Phenotypes

Phenotype Features Present Metabolic Risk Profile

Phenotype A (Classic / Full) Hyperandrogenism + Anovulation + PCOM Highest risk for insulin resistance and metabolic syndrome

  • Phenotype B (Non-PCOM) Hyperandrogenism + Anovulation High metabolic risk
  • Phenotype C (Ovulatory) Hyperandrogenism + PCOM (regular cycles) Intermediate metabolic risk
  • Phenotype D (Non-Androgenic) Anovulation + PCOM (normal androgens) Lowest metabolic risk
  • Differential Diagnosis: Excluding Mimickers

Non-Classic Congenital Adrenal Hyperplasia (NCCAH): Screen with a morning fasting serum 17-hydroxyprogesterone (17-OHP) in the early follicular phase. A value <200 ng/dL rules out 21-hydroxylase deficiency. Levels 200–1,000 ng/dL require cosyntropin (synthetic ACTH) stimulation testing (>1,000 ng/dL confirms NCCAH).

Hyperprolactinemia: Fasting serum prolactin excludes prolactin-secreting adenomas that suppress GnRH.

Thyroid Disorders: Serum TSH excludes hypothyroidism, which increases TRH and secondarily elevates prolactin while decreasing SHBG.

Androgen-Secreting Neoplasms: Suspect with rapid virilization (clitoromegaly, voice deepening, rapid baldness). Total testosterone >200 ng/dL suggests an ovarian tumor (Sertoli-Leydig); DHEAS >700 mcg/dL suggests an adrenal neoplasm. Warrant urgent pelvic ultrasound or adrenal CT/MRI.

Cushing Syndrome: Screen with 24-hour urinary free cortisol or 1-mg overnight dexamethasone suppression test when clinical stigmata (buffalo hump, moon facies, purple striae >1 cm, proximal muscle weakness) are present.

Metabolic Sequelae & Surveillance Protocols

Type 2 Diabetes Screening: Up to 35% of individuals with PCOS have impaired glucose tolerance. A mandatory 2-hour 75g oral glucose tolerance test (OGTT) is recommended at baseline (fasting glucose and HbA1c miss over 50% of abnormal cases in PCOS). Repeat every 1 to 3 years.

Cardiovascular & Lipid Surveillance: Fasting lipid panel every 2 to 3 years. Typical pattern shows high triglycerides (>150 mg/dL), low HDL (<50 mg/dL), and increased small dense LDL particles.

NAFLD / MASLD: Monitor serum transaminases (ALT/AST) for hepatic steatosis driven by insulin resistance.

Obstructive Sleep Apnea (OSA): Screen via validated tools (e.g., STOP-BANG), especially in individuals with obesity or daytime fatigue.

Endometrial Protection: Unopposed estrogen elevates endometrial cancer risk 2- to 6-fold. Evaluate amenorrheic intervals (>3 months) and biopsy patients aged >=45 years or those with persistent abnormal bleeding.

Multimodal Management

Lifestyle & Weight Optimization: First-line foundation. A 5% to 10% weight loss reduces visceral fat, lowers fasting insulin by 30%–50%, increases SHBG, reduces free testosterone, and restores spontaneous ovulatory cycles in up to 50% of overweight patients.

Combined Oral Contraceptives (COCs): First-line pharmacotherapy for non-fertility goals. Ethinyl estradiol suppresses LH secretion (decreasing thecal androgens) and boosts hepatic SHBG synthesis. The progestin prevents endometrial hyperplasia. Low-androgenic progestins (norgestimate, desogestrel) or anti-androgenic progestins ( drospirenone ) are preferred.

Anti-Androgens: Spironolactone (50–200 mg daily) competitively blocks androgen receptors at the pilosebaceous unit and inhibits 5-alpha reductase. Clinical reduction of hirsutism requires 6 to 9 months of therapy. Safety Warning: Spironolactone is teratogenic (causes feminization of male fetuses) and must never be used without reliable contraception (COCs or LARC).

Metformin (1,500–2,000 mg daily): Improves insulin sensitivity and hepatic gluconeogenesis in patients with impaired glucose tolerance or metabolic syndrome.

Ovulation Induction: Letrozole (aromatase inhibitor, 2.5–7.5 mg daily for 5 days starting cycle day 3 or 5) is the first-line agent for infertility in PCOS (superior live-birth and lower multiple gestation rates over clomiphene citrate). Clomiphene citrate remains a second-line SERM alternative.